Kara Elam,  —

Xeomin (incobotulinumtoxinA) has been approved by the U.S. Food and Drug Administration for the treatment of chronic sialorrhea, or excessive drooling, a common condition in amyotrophic lateral sclerosis (ALS) patients. Merz Neurosciences, a division of Merz North America, recently announced that its supplemental biologics license application (sBLA) for Xeomin was…

Advanced neuroimaging techniques and neuropsychological evaluations of patients with amyotrophic lateral sclerosis (ALS) recently confirmed the existence of a unique micro-structural brain degeneration pattern that contributes to memory loss, according to a study conducted by an international research team that included a group from Baylor College of Medicine. The report, “…

AB Science recently announced it has completed its targeted enrollment of 381 patients for an ongoing Phase 3 study evaluating masitinib in the treatment of amyotrophic lateral sclerosis (ALS). Masitinib is an orally administered tyrosine kinase inhibitor designed to target important immune system cells known as mast cells and macrophages. Its mechanism of action…

This week the ALS Association, whose mission is to lead the fight to treat and cure ALS through global research and nationwide advocacy, has highlighted important research from the 2015 Annual Meeting of the Society For Neuroscience, an event that took place in Chicago, Oct. 17–21. This meeting is the premiere venue…

University of Toronto (UT) researchers have uncovered the main genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a discovery that will lead to the development of new efficacious treatments. The work entitled, “Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral…

Researchers from the University of Milan (UM), Italy, have recently released findings from their scientific literature review, in an effort to uncover the causes of cellular pathologies that are the hallmark of Amyotrophic Lateral Sclerosis (ALS). The findings entitled, “SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis“, published…

Last year a monumental push to increase research funding for Amyotrophic Lateral Sclerosis (ALS), known as the ALS Ice Bucket Challenge, raised over $220 million globally for ALS research and patient care.  The video based social media challenge is set to return this year beginning July 31st. Co-founder Pat…

Researchers from the University of Toronto (UT) have recently discovered a potential way to detect a genetic predisposition for Amyotrophic Lateral Sclerosis (ALS), before the debilitating symptoms of the disease begin. The study, entitled, “Jump from Pre-mutation to Pathologic Expansion in C9orf72,” was published in the…

Researchers from the Institute of Pathobiochemistry at the Medical Center of Johannes Gutenberg University Mainz, Germany, have recently released results from a study in which they used animal experiments to assess the possibility that low-frequency alternating magnetic fields (LFMF), such as those generated by overhead power lines, are a…

This week, Kadimastem, an innovative Israeli biotechnology company focused on the industrial development and commercialization of human pluripotent stem cell (hPSC)-based therapeutic solutions for the neurodegenerative diseases Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS), announced that it plans to begin human trials using its stem-cell technology to…